Taxane vs. taxane: Is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: Results of the ERASME 3 study

Breast Cancer Research and Treatment

Volumn 111, Issue 2, 2008, Pages 203-208

  Radaideh, Sofyan M ^a   Sledge, George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; ERASME 3 study; Paclitaxel; Taxane

Indexed keywords

DOCETAXEL; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NOTE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASM METASTASIS; PACLITAXEL; TAXOIDS;

EID: 48149115527     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9776-4     Document Type: Note

References (40)

1. I Ringel SB Horwitz 1991 Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol J Natl Cancer Inst 83 4 288 291
2. FA Holmes RS Walters RL Theriault 1991 Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer J Natl Cancer Inst 83 24 1797 1805
3. V Valero FA Holmes RS Walters 1995 Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J Clin Oncol 13 12 2886 2894
4. G Fountzilas A Athanassiadis A Kalogera-Fountzila 1997 Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group Eur J Cancer 33 11 1893 1895
5. V Dieras B Chevallier P Kerbrat 1996 A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer Br J Cancer 74 4 650 656
6. PM Ravdin HA Burris 3rd G Cook 1995 Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 12 2879 2885
7. WJ Gradishar S Tjulandin N Davidson 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 31 7794 7803
8. NK Ibrahim B Samuels R Page 2005 Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J Clin Oncol 23 25 6019 6026
9. Cassier PA, Chabaud S, Trillet-Lenoir V et al (2007) A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat
10. SE Jones J Erban B Overmoyer 2005 Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 23 24 5542 5551
11. RE Smith AM Brown EP Mamounas 1999 Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26 J Clin Oncol 17 11 3403 3411
12. R Paridaens L Biganzoli P Bruning 2000 Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over J Clin Oncol 18 4 724 733
13. GW Sledge D Neuberg P Bernardo 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 4 588 592
14. CE Geyer Jr SJ Green CM Moinpour 1998 Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study Breast Cancer Res Treat 51 2 169 181
15. JB Vermorken WW ten Bokkel Huinink IA Mandjes 1995 High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial Semin Oncol 22 4 Suppl 8 16 22
16. JF Bishop J Dewar GC Toner 1999 Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer J Clin Oncol 17 8 2355 2364
17. JM Nabholtz K Gelmon M Bontenbal 1996 Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer J Clin Oncol 14 6 1858 1867
18. EP Winer DA Berry S Woolf 2004 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342 J Clin Oncol 22 11 2061 2068
19. JA Sparano 2000 Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials Clin Breast Cancer 1 1 32 40 discussion 1-2
20. AD Seidman CA Hudis J Albanell 1998 Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 10 3353 3361
21. EA Perez CL Vogel DH Irwin JJ Kirshner R Patel 2001 Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 22 4216 4223
22. Seidman A, Berry D, Cirrincione C et al (2004) CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC (abstract)
23. ME O'Brien RC Leonard PJ Barrett-Lee SP Eggleton JP Bizzari 1999 Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group Ann Oncol 10 2 205 210
24. V Harvey H Mouridsen V Semiglazov 2006 Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer J Clin Oncol 24 31 4963 4970
25. HJ Burstein J Manola J Younger 2000 Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 6 1212 1219
26. TM Loffler 1998 Is there a place for "dose-dense" weekly schedules of the taxoids? Semin Oncol 25 5 Suppl 12 32 34
27. E Tomiak MJ Piccart J Kerger 1994 Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis J Clin Oncol 12 7 1458 1467
28. FK Engels J Verweij 2005 Docetaxel administration schedule: from fever to tears? A review of randomised studies Eur J Cancer 41 8 1117 1126
29. Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Clawson A, Hawkins MJ (2007) Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol, 2007 ASCO Annual Meeting Part I. Vol 25, No. 18S (June 20 Supplement), 2007:1032
30. E Bria C Nistico F Cuppone 2006 Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients Cancer 106 11 2337 2344
31. Sparano J, Wang M, Martino S et al (2007) Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk axillary node-negative breast cancer: results of the North American Breast Cancer Intergroup Trial E1199 Abstract). J Clin Oncol. 2007 ASCO Annual Meeting Part I. Vol 25, No. 18S (June 20 Supplement), 2007:516
32. AU Buzdar SE Singletary V Valero 2002 Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial Clin Cancer Res 8 5 1073 1079
33. IC Henderson DA Berry GD Demetri 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 6 976 983
34. EP Mamounas J Bryant B Lembersky 2005 Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 J Clin Oncol 23 16 3686 3696
35. G Fountzilas D Skarlos U Dafni 2005 Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 16 11 1762 1771
36. SE Jones MA Savin FA Holmes 2006 Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 34 5381 5387
37. H Roche P Fumoleau M Spielmann 2006 Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial J Clin Oncol 24 36 5664 5671
38. M Martin T Pienkowski J Mackey 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 22 2302 2313
39. L Goldstein A O'Neill J Sparano 2005 E2197: phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high-risk node negative breast cancer Clin Oncol 23 7s (abstract)
40. HD Bear S Anderson RE Smith 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 13 2019 2027